 Shares of CureVac CVAC, 5.06 gained 2.6 in premarket trading on Thursday after the company said it began dosing participants in a Phase 1 clinical trial assessing an experimental mRNA-based influenza vaccine it developed with GlaxoSmithKline GSK, -2.12 . The open-label study plans to enroll 240 adults. 